Cargando…

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

BACKGROUND: The potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect of empagliflozin on metabolic syndrome rats with prediabetes. METHODS: SHR/NDmcr-cp(+/+) rats (SHRcp), a model of metabolic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusaka, Hiroaki, Koibuchi, Nobutaka, Hasegawa, Yu, Ogawa, Hisao, Kim-Mitsuyama, Shokei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106779/ https://www.ncbi.nlm.nih.gov/pubmed/27835975 http://dx.doi.org/10.1186/s12933-016-0473-7

Ejemplares similares

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
por: Lin, Bowen, et al.
Publicado: (2014)

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure
por: Koibuchi, Nobutaka, et al.
Publicado: (2014)

DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice
por: Ma, MingJie, et al.
Publicado: (2015)

Erratum: ASK1 is involved in cognitive impairment caused by long-term high-fat diet feeding in mice
por: Toyama, Kensuke, et al.
Publicado: (2015)

ASK1 is involved in cognitive impairment caused by long-term high-fat diet feeding in mice
por: Toyama, Kensuke, et al.
Publicado: (2015)

High‐Fat‐Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer's Disease, Independently of Metabolic Disorders
por: Lin, Bowen, et al.
Publicado: (2016)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice
por: Adingupu, Damilola D., et al.
Publicado: (2019)

Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure
por: Takane, Koki, et al.
Publicado: (2017)

Calcium Channel Blockers, More than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats
por: Yamamoto, Eiichiro, et al.
Publicado: (2012)

Correction: Calcium Channel Blockers, More than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats
por: Yamamoto, Eiichiro, et al.
Publicado: (2013)

Long‐Term Renal Denervation Normalizes Disrupted Blood Pressure Circadian Rhythm and Ameliorates Cardiovascular Injury in a Rat Model of Metabolic Syndrome
por: Katayama, Tetsuji, et al.
Publicado: (2013)

Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome—The Critical Role of Angiotensin II
por: Sueta, Daisuke, et al.
Publicado: (2013)

DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
por: Hasegawa, Yu, et al.
Publicado: (2017)

The Authors Reply:
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Low abdominal subcutaneous preadipocyte adipogenesis is associated with visceral obesity, visceral adipocyte hypertrophy, and a dysmetabolic state
por: Lessard, Julie, et al.
Publicado: (2014)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
por: Hu, Zhaoyang, et al.
Publicado: (2021)

High LPL Activity and Adipocyte Hypertrophy Reduce Visceral Fat and Metabolic Risk in Obese, Older Women
por: Serra, Monica C., et al.
Publicado: (2015)

Renal Denervation Prevents Stroke and Brain Injury via Attenuation of Oxidative Stress in Hypertensive Rats
por: Nakagawa, Takashi, et al.
Publicado: (2013)

Visceral Adipocyte Hypertrophy is Associated With Dyslipidemia Independent of Body Composition and Fat Distribution in Women
por: Veilleux, Alain, et al.
Publicado: (2011)

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
por: Connelly, Kim A., et al.
Publicado: (2020)

Lessening Production
Publicado: (1874)

Ivabradine promotes angiogenesis and reduces cardiac hypertrophy in mice with myocardial infarction
por: Wu, Xiangqi, et al.
Publicado: (2018)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Lessen uit 2020
por: Hageman, Alexia
Publicado: (2020)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy
por: Gonzales, Amanda M, et al.
Publicado: (2007)

Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2018)

Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2020)

Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2019)

De lessen van 2020
por: Eskes, Anne, et al.
Publicado: (2020)

Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes
por: Kim, Gyuri, et al.
Publicado: (2015)

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
por: Hiruma, Shigenori, et al.
Publicado: (2021)

Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
por: Witkowski, Marco, et al.
Publicado: (2021)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
por: Lee, Hsiang-Chun, et al.
Publicado: (2019)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Activation of Hypoxia‐Inducible Factor‐2 in Adipocytes Results in Pathological Cardiac Hypertrophy
por: Lin, Qun, et al.
Publicado: (2013)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b2p4apt8ntatevgd25t69aiu14